TABLE 1.
Training cohort (n=166) | Validation cohort (n=137) | |
Asthmatic subjects | 63 (105) | 58 (80) |
Age (years) | 51±16 | 51±15 |
Male | 43 (71) | 36 (50) |
BMI (kg·m−2) | 27±4.8 | 26±4.9 |
Smoking status | ||
Nonsmoker | 52 (87) | 51 (70) |
Ex-smoker | 25 (42) | 31 (42) |
Current smoker | 23 (37) | 18 (25) |
Atopy | 47 (78) | 42 (58) |
FEV1 (% pred) | 92±17 | 94±17 |
FEV1/FVC (%) | 79±8.3 | 79±7.9 |
FENO (ppb) | 21 (14–34) | 19 (13–29) |
Sputum eosinophils (%)# | 1 (0–3) | 1 (0.2–2.5) |
Blood eosinophils (%) | 2.5 (1.3–4.2) | 2.1 (1.2–3.1) |
Blood eosinophils (μL−1) | 170 (98–290) | 160 (81–250) |
Total serum IgE (kU·L−1) | 60 (22–252) | 78 (27–158) |
Data are presented as % (n), mean±sd or median (interquartile range). BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FENO: exhaled nitric oxide fraction. #: n=95 in the training cohort and n=94 in the validation cohort.